OpenAI Unveils GPT-Rosalind AI Model for Life Sciences Research

On April 16, OpenAI introduced GPT-Rosalind, a new AI model aimed at life sciences research.

The model is named after scientist Rosalind Franklin.

Capabilities and use cases

GPT-Rosalind targets work in biochemistry, drug discovery and translational medicine.

OpenAI says it can help with evidence synthesis, hypothesis generation and experimental planning.

Researchers can query databases and ask the model to read recent scientific papers.

It can suggest experiments and integrate with other scientific tools.

Access and tooling

OpenAI launched GPT-Rosalind as a research preview in ChatGPT, Codex and via the API.

Access is available to qualified customers through a trusted access deployment structure.

The company also released a free Life Sciences research plugin for Codex.

The plugin links scientists to more than 50 scientific tools and data sources.

Industry response and partnerships

Demand for AI tools in drug discovery has risen across pharma, academia and biotech.

OpenAI says it is working with Amgen, Moderna and Thermo Fisher Scientific to apply GPT-Rosalind.

Technical context and related models

GPT-Rosalind was built on top of OpenAI’s newest internal models.

OpenAI described the model’s goals in a blog and at a press briefing.

The company also unveiled GPT-5.4-Cyber, a variant tuned for defensive cybersecurity work.

Rival Anthropic recently announced its frontier model, Mythos.

The industry now features multiple frontier AI efforts focused on specialist domains.

Reporting and next steps

Filmogaz.com will monitor developments and report new details as they emerge.

Reporting credit: Juby Babu in Mexico City; editing by Sahal Muhammed.